Leerink Partnrs Comments on Xeris Biopharma FY2025 Earnings

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) – Stock analysts at Leerink Partnrs raised their FY2025 EPS estimates for Xeris Biopharma in a research note issued on Wednesday, November 12th. Leerink Partnrs analyst R. Ruiz now forecasts that the company will earn $0.02 per share for the year, up from their prior forecast of $0.01. The consensus estimate for Xeris Biopharma’s current full-year earnings is ($0.41) per share. Leerink Partnrs also issued estimates for Xeris Biopharma’s FY2026 earnings at $0.31 EPS, FY2027 earnings at $0.70 EPS and FY2028 earnings at $1.06 EPS.

XERS has been the subject of several other research reports. Piper Sandler raised their price target on shares of Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. Leerink Partners increased their price objective on Xeris Biopharma from $7.00 to $9.00 and gave the company an “outperform” rating in a research note on Tuesday, August 19th. Wall Street Zen cut Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Saturday, November 8th. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Xeris Biopharma in a report on Friday, November 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Xeris Biopharma in a research note on Wednesday, October 8th. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Xeris Biopharma presently has an average rating of “Moderate Buy” and a consensus target price of $9.58.

Xeris Biopharma Stock Performance

Shares of XERS stock opened at $7.08 on Monday. The stock has a market capitalization of $1.17 billion, a P/E ratio of -70.79 and a beta of 0.21. The company has a 50 day moving average price of $8.33 and a 200 day moving average price of $6.54. Xeris Biopharma has a fifty-two week low of $2.86 and a fifty-two week high of $10.08.

Insiders Place Their Bets

In other news, Director Jeffrey W. Sherman sold 42,232 shares of the firm’s stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $7.92, for a total transaction of $334,477.44. Following the sale, the director owned 219,188 shares of the company’s stock, valued at approximately $1,735,968.96. This trade represents a 16.15% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Marla Persky sold 15,500 shares of the company’s stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $7.72, for a total value of $119,660.00. Following the completion of the transaction, the director directly owned 142,000 shares of the company’s stock, valued at $1,096,240. This trade represents a 9.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 97,641 shares of company stock worth $750,859. Insiders own 4.56% of the company’s stock.

Institutional Investors Weigh In On Xeris Biopharma

Several hedge funds and other institutional investors have recently bought and sold shares of XERS. AlphaQuest LLC acquired a new position in Xeris Biopharma in the third quarter valued at $35,000. Xponance Inc. purchased a new stake in shares of Xeris Biopharma in the 1st quarter valued at about $57,000. FORA Capital LLC acquired a new stake in shares of Xeris Biopharma in the 1st quarter valued at about $60,000. Northwestern Mutual Wealth Management Co. grew its stake in Xeris Biopharma by 179.3% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock worth $63,000 after buying an additional 5,000 shares during the last quarter. Finally, State of Alaska Department of Revenue purchased a new position in Xeris Biopharma during the 3rd quarter worth approximately $68,000. 42.75% of the stock is currently owned by institutional investors and hedge funds.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.